Finanza

Global Blood Therapeutics, Inc.: Oppenheimer rivaluta il giudizio Buy e il rating passa a Neutral

This content has been archived. It may no longer be relevant

Global Blood Therapeutics, Inc.: Oppenheimer rivaluta il giudizio Buy e il rating passa a Neutral

Global Blood Therapeutics


FIMA2681# 2022-08-08T21:01:02+02:00

Show More